ALS Network Legislation to Extend Key ALS Programs Clears Congress
The ACT for ALS Reauthorization Act has received final congressional passage, extending critical research and therapy access programs through 2031. The legislation awaits presidential signature before the September 30 expiration.
ALS Network is celebrating the final congressional passage of the ACT for ALS Reauthorization Act of 2026. The bipartisan legislation, which extends key ACT for ALS programs through 2031, has been sent to the President's desk for signature ahead of the current authorization's expiration on September 30.
The law supports advancements in ALS research, shared research infrastructure, and expanded access to investigational therapies. The reauthorization aims to prevent disruption to programs that facilitate evidence-generating expanded access, natural history and biomarker research, and coordination within the ALS research community.
Spearheaded by Representatives Mike Quigley and Ken Calvert in the House, and Senators Lisa Murkowski and Chris Coons in the Senate, the bill secured bipartisan support. ALS Network was actively involved, providing policy recommendations and mobilizing advocates from the ALS community to Capitol Hill.
"Final congressional passage is a major win for people living with ALS and their families," said ALS Network President and CEO Sheri Strahl. "We are proud of the role we played and are grateful to every advocate who persisted to help carry this legislation across the finish line."